Your Wednesday Evening Leronlimab Update: The Mystery

New Post Public Reply Private Reply Replies (4) Message Board
Respert24
1,567
Your Wednesday Evening Leronlimab Update: The Mystery Meetings Edition

(Sponsored by an almost completed bottle of Pure Paso by J Lohr)

(Update: Completed)

Today we failed to get any sort of news out of the big UK meeting. It's still sort of early and maybe we get one of those odd 9:32pm press releases, but the betting public disagrees with this sentiment as we've seen the line move significantly in favor of no announcement today. Current odds for an announcement before the bell opens tomorrow are at a dismal 20-1.

Analysis: You have a better chance at curing Covid with Remdesivir than you do getting an update about the UK today. That being said, they asked for our information surrounding manufacturing, efficacy, and safety so they could review it prior to this meeting. That means they can, or maybe have, come to a conclusion about the validity of Leronlimab as a treatment for Covid. The hour could very well have been about shoring up the details and setting the expectations/executables for pulling the approval trigger. I feel like "pre BLA" was a deceiving way to explain this meeting. Every day we don't have to start another trial or hear about being denied approval is a very big deal. Logic says they would have said no by now if it was a no.

We are now a full day from the meeting with the FDA and still no update. Do they want to help us? Are they slow playing us? Do they even really know what Leronlimab is and what it can do? Does the lack of an update inadvertently give us an update as no news could be construed as good news? Did I spell inadvertently incorrectly and have to go back to fix it? How many questions can a guy ask in a row before it gets weird? Is it already weird? Who defines what weird is anyway?

Analysis: You've got a higher chance of Plasma becoming the standard of Covid care than you do of Leronlimab failing to get an approval. I think that since we haven't gotten bad news after all this time we can reasonably assume that we're in a decent/good position surrounding approval. On a call from what seems like 11 years ago, JL mentioned that Cytodyn had gone to the FDA asking for EUA something like 4 times from early in the Montefiore days to much later once EINDs were happening on the west coast as well. Every time they denied us. Yet here we are 3-4 weeks in with hopes still high.

SPEED ROUND!

NP & BP - It's all good between them. They were recently seen together at Nobu eating soba noodles from opposite ends of the noodle, Lady and the Tramp style.

NASDAQ - More like NAS-WHATTHEHECKISTHEHOLDUP amiright? Thank you, I'll be here all week. Tip your waitstaff.

SHAREHOLDER VOTE - Not unlike the bicycle dance scene from the movie RAD, this subject has become a lightning rod of opposing views. I think we can all agree that no matter the outcome, Cru Jones was basically the BMX version of Leronlimab. Scrappy, unknown but worthy, good at dancing on bikes, wins in the end. You get it.

MANUFACTURING - We likely can't squeeze more out of 2020 because it's late and outside of our 1.5mil vials already scheduled and paid for, Samsung is apparently contracted out. But next year is wide open like <insert Adam Feurstein mama joke here> and we should be able to negotiate a massive increase in production with those sweet, sweet Euros the UK soon throws at us.

MESSAGE BOARDS - Ihub is now 95% disingenuous dbags and I applaud those of you who have finally made the move here. YMB is a close terrible second, with that main difference being a few less bashers but far more political BSrs. This is clearly the best board and for that I'm grateful.

PREDICTIONS

I someday have a beach house or boat called "Twenty Nine Cents", named after the cheapest CYDY shares I was able to acquire. Leronlimab is as well known to the public as drugs like the Z-Pack or Allegra. I become an insufferable wine snob as my wine budget grows to unheard of proportions. But best of all, people around the world stop dying needlessly from Covid and the tide changes for the better. Hold onto your shares. Great things are ahead and whether it's tomorrow or in a month we have yet to have any evidence that Leronlimab doesn't have the goods.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First Industrial Declares Regular Dividend Amid Growth Insights

Updated Category News Views 75

Dividend Declaration Reflects Confidence First Industrial Realty Trust, folks, just put another office stamp on their ongoing reliability quest—and I'm talking dividends. They're shelling out a tidy $0.50 per share for Q4 2026, with stockholders due to see the cash on January 19, 2027. That's like clockwork precision, showing a steadiness in what some call the unruly...

Continue Reading
Trimble's Q3 2026: Guidance Update and Record ARR

Updated Category News Views 48

Trimble Smashes Through Q3 Expectations Trimble Inc. (NASDAQ:TRMB) tossed a bit of a curveball by posting Q3 2026 results that sailed past analyst forecasts. We’re talking revenue swelling to $966.8 million, a decent 7% bump from the previous year. Now, for a company riding its 'Connect & Scale' strategy, this serves as a validation of its aggressive scaling ambitions....

Continue Reading
Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Updated Category News Views 93

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

Continue Reading
Zuellig Pharma Expands Clinical Capabilities in China

Updated Category News Views 86

Zuellig Pharma's Strategic Leap in Hangzhou You know, in the ever-evolving world of biotech and pharmaceuticals, setting up shop in the right locale can mean the difference between breakthroughs and breakdowns. So Zuellig Pharma—a major player, but not exactly a household ticker—made a smart move acquiring a clinical facility in Hangzhou. This is no minor shuffle;...

Continue Reading
Natixis' $100M Student Challenge Mixes Real Stakes

Updated Category News Views 56

Opportunity Knocks for Budding Portfolio Managers Picture this: You're a student, neck-deep in textbooks and theories, and then bam! You're handed the keys to manage a $100 million portfolio. That's the real-deal opportunity Natixis Investment Managers is dangling with its seventh Students Challenge. Diving Into the Nuts and Bolts Listen up, kids. Applications are open...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
Coretek Joins CRN's Elite AI Innovators of 2026

Updated Category News Views 69

Coretek's Leap to AI Innovator Status Here we are, folks. Another announcement hits the wires that showcases a company's ascent amid the swelling AI tide. Coretek, hailing from Farmington Hills, managed to snag a spot on CRN's inaugural 2026 AI Innovators list. No small potatoes, if you ask me, considering the competition on this playing field. Why the fuss? It's about...

Continue Reading
Allego Dominates 2026 Gartner Magic Quadrant: Why It Matters

Updated Category News Views 40

Allego Secures Top Spot Yet Again I've seen companies rise and fall on the whims of industry recognition, and let me tell ya, Allego's riding high on the right wave. For the second year running, this outfit's been named a Leader in the 2026 Gartner Magic Quadrant for Revenue Enablement Platforms. Recognized for its Completeness of Vision—yeah, that's no small feat...

Continue Reading
KOVE's Bold Lineup Expansion at EICMA 2026

Updated Category News Views 112

What's Roaring: The Latest from KOVE Anybody who’s been following motorcycle trends knows that EICMA 2026 was destined to be a spectacle, and KOVE didn’t disappoint. They rolled out a fleet of five new models, including the 125 RALLY, 350 RALLY, 650RR, and two head-turners on the electric front: the BONIC and the E-500RR. Each model brings something fresh to the...

Continue Reading
Askey & Icom Team Up: Trading Airwaves for Partnerships

Updated Category News Views 6

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...

Continue Reading

Top 5 Most Recently Viewed Articles

Tesla's Earnings Impact: A Preview for Investors Ahead

Updated Category News Views 206

Tesla's Earnings and Market Dynamics As we gear up for Tesla's earnings announcement, all eyes are turning to the electric vehicle giant (NASDAQ: TSLA). Tesla is leading the charge as the first among the prominent group of tech companies known as the "Magnificent Seven" to reveal its financial performance. The anticipation builds as markets reflect on how business...

Continue Reading
Atos Group Releases Detailed Half-Year Financial Report for 2025

Updated Category News Views 222

Atos Group Updates on Financial Performance for 2025 Availability of the 2025 Half-year Financial Report Atos Group has made significant strides in its financial reporting for 2025, announcing the release of its half-year financial report. This document was published on the Atos website and was also filed with the French Financial Markets Authority (AMF). Insights from...

Continue Reading
Anywhere Real Estate and Canva Team Up for Agents' Success

Updated Category News Views 204

Anywhere Real Estate's Exciting New Partnership Anywhere Real Estate Inc. (NYSE: HOUS), a global frontrunner in the residential real estate sector, has recently unveiled an impactful collaboration with Canva, a recognized visual communication platform. This agreement aims to empower Every agent within their extensive network. Enhanced Tools for Affiliated Agents This...

Continue Reading
THEON Showcases Innovative A.R.M.E.D. Ecosystem at IDEX 2025

Updated Category News Views 279

THEON Unveils Revolutionary A.R.M.E.D. Ecosystem At IDEX 2025, THEON made a significant impact by showcasing its A.R.M.E.D. (Augmented Reality Modular Ecosystem of Devices), designed to elevate the capabilities of tomorrow's soldiers. This integrated solution promises to improve tactical awareness, effectiveness, and survivability for modern combat operatives....

Continue Reading
Exploring Advances in Arthrogryposis at Montreal Symposium

Updated Category News Views 304

4th International Symposium on Arthrogryposis Unveiled in Montreal MONTREAL — The Shriners Hospitals for Children - Canada is set to host the much-anticipated 4th International Symposium on Arthrogryposis from September 28 to October 1. This initiative brings together renowned healthcare professionals and researchers from various pediatric centers in Montreal,...

Continue Reading